210 related articles for article (PubMed ID: 27661113)
1. Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes.
Tseng CH
Oncotarget; 2017 Mar; 8(12):19057-19064. PubMed ID: 27661113
[TBL] [Abstract][Full Text] [Related]
2. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes.
Tseng CH
Oncotarget; 2016 Sep; 7(38):62687-62696. PubMed ID: 27409676
[TBL] [Abstract][Full Text] [Related]
3. Sitagliptin May Reduce Breast Cancer Risk in Women With Type 2 Diabetes.
Tseng CH
Clin Breast Cancer; 2017 Jun; 17(3):211-218. PubMed ID: 27986440
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes.
Tseng CH
Eur J Clin Invest; 2016 Jan; 46(1):70-9. PubMed ID: 26584246
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes.
Tseng CH
Oncotarget; 2016 Apr; 7(17):24871-9. PubMed ID: 27029076
[TBL] [Abstract][Full Text] [Related]
6. Metformin use and cervical cancer risk in female patients with type 2 diabetes.
Tseng CH
Oncotarget; 2016 Sep; 7(37):59548-59555. PubMed ID: 27486978
[TBL] [Abstract][Full Text] [Related]
7. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan.
Tseng CH
Ann Med; 2015; 47(7):561-9. PubMed ID: 26426676
[TBL] [Abstract][Full Text] [Related]
9. Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
Tseng CH
Oncotarget; 2017 Mar; 8(12):18802-18810. PubMed ID: 27861146
[TBL] [Abstract][Full Text] [Related]
10. Use of metformin and risk of kidney cancer in patients with type 2 diabetes.
Tseng CH
Eur J Cancer; 2016 Jan; 52():19-25. PubMed ID: 26630530
[TBL] [Abstract][Full Text] [Related]
11. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus.
Tseng CH
Aging (Albany NY); 2016 Aug; 8(8):1636-49. PubMed ID: 27587088
[TBL] [Abstract][Full Text] [Related]
12. Metformin and lung cancer risk in patients with type 2 diabetes mellitus.
Tseng CH
Oncotarget; 2017 Jun; 8(25):41132-41142. PubMed ID: 28456789
[TBL] [Abstract][Full Text] [Related]
13. Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis.
Tseng CH
Diabetes Metab; 2017 Oct; 43(5):438-445. PubMed ID: 28438547
[TBL] [Abstract][Full Text] [Related]
14. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
Tseng CH
Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555
[TBL] [Abstract][Full Text] [Related]
15. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes.
Tseng CH
Acta Diabetol; 2014 Apr; 51(2):295-303. PubMed ID: 24509842
[TBL] [Abstract][Full Text] [Related]
16. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.
Tseng CH
Liver Int; 2018 Nov; 38(11):2018-2027. PubMed ID: 29956875
[TBL] [Abstract][Full Text] [Related]
17. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan.
Tseng CH
Gynecol Oncol; 2015 Jul; 138(1):147-53. PubMed ID: 25913129
[TBL] [Abstract][Full Text] [Related]
18. Metformin reduces risk of varicose veins in patients with type 2 diabetes.
Tseng CH
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3206. PubMed ID: 31322821
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin and oral cancer risk in type 2 diabetes patients.
Tseng CH
Oncotarget; 2017 Nov; 8(57):96753-96760. PubMed ID: 29228568
[TBL] [Abstract][Full Text] [Related]
20. Metformin may reduce oral cancer risk in patients with type 2 diabetes.
Tseng CH
Oncotarget; 2016 Jan; 7(2):2000-8. PubMed ID: 26683519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
